MMWR. Morbidity and mortality weekly report · 2026
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maloney Patrick, Reeves Emily L, Wielgosz Kristina, Price Ashley M, Natarajan Karthik, DeSilva Malini B, Dascomb Kristin, Klein Nicola P, Tartof Sara Y, Irving Stephanie A, Grannis Shaun J, Ong Toan C, Weber Zachary A, Schuster Jennifer E, Zerr Danielle M, Michaels Marian G, Boom Julie A, Halasa Natasha B, Staat Mary A, Weinberg Geoffrey A, House Stacey L, Saade Elie A, Geffel Krissy Moehling, Gaglani Manjusha, Wernli Karen J, Murugan Vel, Martin Emily T, Bontrager Natalie A B, Kirby Marie K, Payne Amanda B, Dawood Fatimah S, Tannis Ayzsa, Moline Heidi L, Zhao Sifang Kathy, Adams Katherine, DeCuir Jennifer, Olson Samantha M, Chung Jessie R, Lewis Nathaniel, Flannery Brendan, Reed Carrie, Garg Shikha, Ellington Sascha, CDC Influenza Vaccine Effectiveness Collaborators, CDC Influenza Vaccine Effectiveness Collaborators
Аннотация
In the United States, annual influenza vaccination has been recommended for all persons aged ≥6 months, including during the 2025-26 season. Interim influenza vaccine effectiveness (VE) estimates were calculated for patients with acute respiratory illness-associated outpatient visits and hospitalizations from three U.S. respiratory virus VE networks during the 2025-26 influenza season, using a test-negative case-control design. Among children and adolescents aged <18 years, VE was 38%-41% against influenza outpatient visits and 41% against influenza-associated hospitalization. Among adults aged ≥18 years, VE was 22%-34% against influenza outpatient visits and 30% against influenza-associated hospitalization. Among children and adolescents, VE against influenza A ranged from 37% (against outpatient visits) to 42% (against hospitalization) across settings; among adults, VE against influenza A ranged from 30% (against hospitalization) to 34% (against outpatient visits) across settings. Among children and adolescents, VE against influenza A(H3N2)-associated outpatient visits was 35% and against influenza A(H3N2)-associated hospitalization was 38%. VE against influenza B outpatient visits ranged from 45%-71% among children and adolescents and was 63% among adults. Other estimates of VE were not statistically significant or were not reportable. Although interim influenza VE is lower during the 2025-26 influenza season than it was during recent influenza seasons, these findings demonstrate that influenza vaccination still provides protection against influenza. CDC recommends influenza vaccination; U.S. influenza vaccines remain available for persons aged ≥6 months.